Open Access Open Badges Research article

Analysis of growth factor signaling in genetically diverse breast cancer lines

Mario Niepel1, Marc Hafner1, Emily A Pace2, Mirra Chung1, Diana H Chai2, Lili Zhou1, Jeremy L Muhlich1, Birgit Schoeberl2* and Peter K Sorger1*

Author Affiliations

1 HMS LINCS Center, Department of Systems Biology, Harvard Medical School, 200 Longwood Ave, WAB 444, Boston, MA 02115, USA

2 Merrimack Pharmaceuticals, 1 Kendall Sq, Cambridge, MA 02139, USA

For all author emails, please log on.

BMC Biology 2014, 12:20  doi:10.1186/1741-7007-12-20

Published: 21 March 2014



Soluble growth factors present in the microenvironment play a major role in tumor development, invasion, metastasis, and responsiveness to targeted therapies. While the biochemistry of growth factor-dependent signal transduction has been studied extensively in individual cell types, relatively little systematic data are available across genetically diverse cell lines.


We describe a quantitative and comparative dataset focused on immediate-early signaling that regulates the AKT (AKT1/2/3) and ERK (MAPK1/3) pathways in a canonical panel of well-characterized breast cancer lines. We also provide interactive web-based tools to facilitate follow-on analysis of the data. Our findings show that breast cancers are diverse with respect to ligand sensitivity and signaling biochemistry. Surprisingly, triple negative breast cancers (TNBCs; which express low levels of ErbB2, progesterone and estrogen receptors) are the most broadly responsive to growth factors and HER2amp cancers (which overexpress ErbB2) the least. The ratio of ERK to AKT activation varies with ligand and subtype, with a systematic bias in favor of ERK in hormone receptor positive (HR+) cells. The factors that correlate with growth factor responsiveness depend on whether fold-change or absolute activity is considered the key biological variable, and they differ between ERK and AKT pathways.


Responses to growth factors are highly diverse across breast cancer cell lines, even within the same subtype. A simple four-part heuristic suggests that diversity arises from variation in receptor abundance, an ERK/AKT bias that depends on ligand identity, a set of factors common to all receptors that varies in abundance or activity with cell line, and an “indirect negative regulation” by ErbB2. This analysis sets the stage for the development of a mechanistic and predictive model of growth factor signaling in diverse cancer lines. Interactive tools for looking up these results and downloading raw data are available at webcite.

Breast cancer; Microenvironment; Receptor tyrosine kinases; Signal transduction; Growth factors